Tumor microvasculature in liver tumors

The tumor microvasculature in liver tumors, particularly in hepatocellular carcinoma (HCC), represents a complex, disorganized network of blood vessels that are structurally and functionally distinct from normal hepatic vasculature (Morse et al., 2019). These vessels are characterized by high permeability, tortuous architecture, and incomplete basement membranes, which are primarily driven by the overproduction of Vascular Endothelial Growth Factor (VEGF) and other pro-angiogenic cytokines (Llovet et al., 2018). This pathological angiogenesis is a hallmark of liver cancer, facilitating rapid tumor growth by providing oxygen and nutrients while also serving as a route for metastatic spread (Mazzaferro et al., 2014). In clinical practice, this microvasculature is a major therapeutic target for anti-angiogenic agents such as bevacizumab, sorafenib, and lenvatinib, which aim to disrupt the VEGF signaling pathway to starve the tumor or normalize the vessels for better drug delivery (Finn et al., 2020; Jain, 2014). Monitoring the state of the microvasculature through biomarkers like microvessel density (MVD) or functional imaging is essential for evaluating treatment efficacy (Kudo, 2018). However, targeting these vessels poses significant safety challenges, including risks of severe hemorrhage and hypertension, especially in patients with underlying liver cirrhosis (Llovet et al., 2018).

Other names

Hepatic tumor vasculatureTumor-associated angiogenesis in the liverLiver cancer microvesselsTumor microvessel density

Inhibition of the Vascular Endothelial Growth Factor (VEGF) signaling pathway and other pro-angiogenic tyrosine kinases to disrupt tumor blood supply and induce vascular normalization.